Core Viewpoint - The resignation of core technical personnel, Mr. Zhu Hua, will not adversely affect the company's operational capabilities, research and development strength, or core competitiveness [1][7]. Group 1: Resignation Details - Mr. Zhu Hua resigned for personal career development reasons and will no longer hold any position within the company [1]. - Mr. Zhu Hua has been with the company since 2020, serving in various roles including Technical Director and Chief Engineer, and was recognized as a core technical personnel in July 2022 [1]. - There are no disputes or potential disputes regarding job results or intellectual property related to Mr. Zhu's departure, ensuring the integrity of the company's patents and intellectual property [1][3]. Group 2: Impact on the Company - The company has a rich reserve of research personnel, with 428 R&D staff members as of June 2024, accounting for 28.90% of the total workforce, including 173 with master's or doctoral degrees [4]. - The company has established a mature and comprehensive R&D system, with six drug research institutes in various locations, ensuring that R&D activities do not heavily rely on individual personnel [6]. - The company's production and R&D activities are currently operating normally, with Mr. Zhu's work having been successfully handed over [6][8]. Group 3: Measures Taken by the Company - The company has a complete technical R&D team structure and a robust management system, with sufficient backup personnel to support ongoing core technology development and innovation [8]. - A comprehensive talent cultivation system is in place, allowing for dual career paths in technical and management roles, ensuring a steady supply of talent for R&D innovation [8].
成都苑东生物制药股份有限公司 关于核心技术人员离职的公告